New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCJC-1295 vs SS-31 (Elamipretide)

CJC-1295 vs SS-31 (Elamipretide)

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
CJC-1295
Anti-Aging & Longevity
SS-31 (Elamipretide)
Summary
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
Half-Life
~30 minutes (No DAC) / 6–8 days (with DAC)
~2–5 hours
Admin Route
SubQ
SubQ
Research
Typical Dose
100 mcg
5–10 mg
Frequency
Once daily, before bed
Daily to several times per week
Key Benefits
  • Sustained increase in growth hormone levels
  • Enhanced muscle growth and strength
  • Improved fat metabolism and body composition
  • Better recovery and tissue repair
  • Increased bone density
  • Enhanced immune function
  • Improved skin quality and collagen production
  • Synergistic GH release when combined with GHRPs like Ipamorelin
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
Side Effects
  • Water retention / puffiness
  • Carpal tunnel syndrome (with prolonged use)
  • Injection site irritation
  • Hunger increase (minor)
  • +1 more
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
Stacks With